Clearer label. Confident care. Relief dogs can feel. For allergic dogs, and the teams who advocate for them, every day with relentless itch is a day too long. Throughout 2025, Canadian veterinarians have put Zenrelia (ilunocitinib tablets) to work breaking the itch–scratch cycle with fast, continuous relief and simple once-daily dosing. Now, the Canadian label has been updated by the Veterinary Drugs Directorate (VDD) of Health Canada, removing prior cautionary wording related to booster vaccinations and offering clearer guidance for everyday practice.

What’s changed?

Upon a review and further evaluation of supplemental scientific data, the VDD has amended the Canadian Zenrelia label to say:

• “Zenrelia modulates the immune system. Dogs should complete their primary vaccination series at least 28 days before initiating Zenrelia treatment. Core booster vaccinations may be given without interruption of Zenrelia use.”¹

This change to the cautionary wording differentiates between primary and booster vaccinations and aligns Canadian guidance more closely with other global markets, improving confidence in recommending fast itch control.

In the year since launch, a growing number of peer-reviewed papers, such as a study on administration of booster vaccines along with Zenrelia², have been published reinforcing Zenrelia’s safety and efficacy in canine allergic dermatitis and atopic dermatitis, including rapid reductions in pruritus and sustained itch control with once daily dosing^3,4. These findings are now reflected in the updated label and clarify vaccination timing without disrupting care, helping teams keep dogs comfortable while staying on their current medication.

What this means for you and your patients

Clinicians can prescribe with full confidence, maintain therapy through routine booster visits, and keep conversations simple for pet owners. Just uninterrupted relief for itchy dogs and streamlined workflows for busy teams. And with once‑daily dosing that doesn’t require loading or tapering, treatment plans remain easy to start, adjust and sustain as seasons and symptoms change.

Ultimately, the label update affirms what clinicians have been seeing: fast, reliable itch control with a strong safety profile. With more than 800,000 dogs treated worldwide,⁵ Zenrelia simplifies the treatment process for allergic dermatitis and helps more dogs get the relief they need, so your team can focus on what matters most: restoring comfort, preserving trust and letting dogs get back to normal.

Learn more at zenrelia.ca

The label contains complete use information, including cautions and warnings. Always read, understand and follow the label and use directions. Zenrelia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2025 Elanco.

Sources

¹ Zenrelia Canadian Product Label

² Fent G, et al. BMC Veterinary Research 2025 21;481 (v1.0)

³ Forster S, et al. Veterinary Dermatology 2025; 36:825-837 (v2.0)

⁴ Forster S, et al. Veterinary Dermatology 2025 36;647-659 (v2.0)

⁵ Elanco DOF, Global Number of dogs treated with Zenrelia – Sept 2025, (v2.0) – 805 821 dogs (p.2) 805,821